In 2017, PhRMA presented a plan to Trump focusing on drug pricing. The group aimed to influence his policies by emphasizing value-based contracting and targeting pharmacy benefit managers. Challenges to drug price negotiation programs are ongoing in court, while a new program addresses pediatric cancer drug shortages.